Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced the initiation of two new clinical trials of ZFP Therapeutics, a Phase 2b study ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE